The 6 highest-scored Precision Oncology companies in the AskCyborg corpus, ranked by Cyborg Score — a 1–10 rating from a bull-vs-bear AI analyst debate across 11 dimensions. Leading the table: Revolution Medicines, Inc. (8/10), Tyra Biosciences, Inc. (8/10), Erasca, Inc. (7/10).
| # | Company | Cyborg Score | The verdict | Ownership | Peers |
|---|---|---|---|---|---|
| 1 | Revolution Medicines, Inc. | 8/10 | Specialized RAS-oncology company with late-stage lead asset, FDA priority designation, and significant market opportunity if clinical trials | Public | |
| 2 | Tyra Biosciences, Inc. | 8/10 | Clinical-stage FGFR3-focused biotech with differentiated selectivity profile, strong cash position, multiple upcoming catalysts, and bullish | Public | |
| 3 | Erasca, Inc. | 7/10 | Erasca offers promising early-stage oncology assets targeting a massive TAM with validated biology and favorable clinical signals, though de | Public | |
| 4 | Acrivon Therapeutics, Inc. | 6/10 | Precision oncology biotech with validated biomarker platform and potentially registrational Phase 2b data in underserved endometrial cancer | Public | |
| 5 | Personalis, Inc. | 5/10 | High-risk, high-reward opportunity in precision oncology with viable long-term potential pending path to profitability and MRD market adopti | Public | |
| 6 | PMV Pharmaceuticals, Inc. | 4/10 | Early-stage precision oncology play with promising clinical data but heightened execution risk and significant capital burn before potential | Public |
See also Precision Oncology industry research and the full industry ratings index.
Cyborg Scores (1–10) are synthesized by AskCyborg’s multi-agent analyst-debate framework across 11 dimensions, recalibrated weekly. How the score works · Methodology.